Background
==========

Osteoporosis is one of the most prevalent chronic health conditions. This condition is characterized by low bone mineral density and microarchitectural deterioration of bone tissue leading to increased bone fragility and risk of fracture \[[@B1]\]. It is estimated that approximately 40% of white women and 13% of men 50 years and older will experience at least one clinically recognized hip, spine or distal forearm fragility fracture in their lifetime \[[@B2]\]. These fractures result in physical, psychological and emotional disabilities, and increased pain that can negatively influence quality of life \[[@B3],[@B4]\].

Osteoporosis can be identified early during the course of the disease by diagnostic tests. Bone mineral density measurements provide the single best method for predicting fracture risk \[[@B5]\] but densitometers are occasionally not available and since the pathogenesis of fragility fractures is multifactorial, bone mass is not the only factor that determines risk.

A number of factors have been found to be associated with fragility fractures, they include advanced age, positive family history, height, existing fracture, propensity to falls, and postural instability \[[@B5]-[@B7]\]. Unfortunately, our understanding of risk factors is still inadequate and thus, there is a need for further research. The identification of new risk factors should focus on their usefulness in clinical situations such that they are easily measured, applicable to all patients, and contribute prognostic information that is independent of bone mineral density. The size of the gap between the costal margin and pelvic ridge (iliocostal distance) may be validated to be a surrogate measure for the presence of osteoporosis and/or vertebral fragility fractures and thereby may be a risk factor for future fracture. Hence, the purpose of this cross-sectional study was to examine the association between iliocostal distance and vertebral and non-vertebral fractures in women and men who were seen in a clinical setting.

Methods
=======

Study design
------------

Patient data were obtained from the Canadian Database of Osteoporosis and Osteopenia (CANDOO). CANDOO consists of approximately 10000 patients and involves 8 sites across Canada (Calgary, Saskatoon, Winnipeg, Hamilton, Toronto, Montreal \[2 sites\], and Quebec City). This database is a prospective registry designed to compile a comprehensive set of osteoporosis-related clinical information \[[@B8]\]. All patients referred to us and seen during the course of routine specialist care were enrolled in CANDOO. Patients data are aggregated using anonymous patient identifiers into a centrally maintained, fully keyed and encoded relational database. In particular, the CANDOO contains electronically stored information regarding basic patient demographics, fracture history, gynecological history, past use of osteoporosis-related drug treatment, drug side effects, past use of corticosteroids and other medications, dietary calcium intake, smoking habits, type and quantity of physical activities, fall history, past medical history and family history including fractures, a self administered osteoporosis health related quality of life instrument, basic laboratory results, and bone density measurements. One database record, with over 400 data fields per patient, is generated for each patient at each clinical visit.

For the current analysis, the database was searched for women and men who had iliocostal distance measurements, and who were seen at the Saskatoon site. The Saskatoon location was chosen because it was the only CANDOO site that recorded iliocostal distance values.

Iliocostal distance measurements and the number of prevalent fractures
----------------------------------------------------------------------

Iliocostal distance was defined as the number of cm between the costal margin and the pelvic ridge of a patient, measured in the midaxillary line (figure [1](#F1){ref-type="fig"}). The measurement was determined by one investigator (WPO) using fingerbreadths (1 finger = 2 cm). All patients were standing during the measurement. Prevalent vertebral and non-vertebral fractures were determined using the CANDOO questionnaire (\"Have you ever had any fractures?\"). Vertebral fractures may or may not have been confirmed by x-ray. Non-vertebral fractures included the ankle, arm, clavicle, elbow, foot, heel, hand, hip, knee, leg, nose, pelvis, rib, shoulder, sacrum, and wrist. Multivariable linear regression analyses were conducted to determine the relationship between iliocostal distance and the number of vertebral and non-vertebral fractures.

![**Measurement Technique for Iliocostal Distance.** Represents iliocostal distance. Iliocostal distance was defined as the number of cm between the costal margin and the pelvic ridge of a patient, measured in the midaxillary line.](1471-2474-3-22-1){#F1}

Potential confounding variables
-------------------------------

Potential confounding variables collected from CANDOO included age; height; weight; menopausal status; age at menopause; lumbar spine, trochanter, femoral neck, and Ward\'s triangle bone mineral density (measurements were made by dual energy x-ray absorptiometry using Hologic or Lunar densitometers); prevalent vertebral fracture status (yes/no); and prevalent non-vertebral fracture status (yes/no); smoking status (never, previously, previously with interruptions, currently, currently with interruptions); family history of fracture (yes/no); number of alcoholic beverages consumed per week (including beer, wine and liquor); number of falls during the last 12 months; dietary calcium intake per day (measured as mg/d and estimated by a food frequency questionnaire); number of minutes spent exercising per week (such as walking, stair climbing, jogging, swimming, bicycling, dancing, skiing and others); current medication use (etidronate, alendronate fluoride, raloxifene, hormone replacement or corticosteroids); calcium supplement status (yes/no); vitamin D supplement status (yes/no); and co-morbid conditions (lung disease, liver disease, thyroid disease, cancer, visual problems that are not corrected by eyeglasses or contacts, osteoporosis, inflammatory bowel disease, epilepsy, coronary disease, cerebrovascular disease, rheumatoid arthritis, diabetes, and kidney failure).

Statistical analysis
--------------------

All multivariable regression analyses were conducted separately for women and men. We determined regression coefficient estimates as well as 95% confidence intervals (CI) of the estimates. All factors listed in the potential confounding variable section were assessed separately for their association with the number of fractures. Variables with a p-value \< 0.2 were included in the multivariable analysis. Variables with a high degree of multicollinearity were removed. Model selection was determined using a stepwise procedure. If necessary, the iliocostal distance variable was force into the final model. All statistical analyses were performed on a Dell computer using the SAS/STAT (version 8.1; SAS Institute Inc., Cary, NC, USA) software package.

Results
=======

A total of 549 patients including 508 women and 41 men participated in this cross-sectional study. Table [1](#T1){ref-type="table"} shows patients\' characteristics at study entry for both women and men. A total of 142 women and 18 men had prevalent vertebral fractures, and 185 women and 21 men had prevalent non-vertebral fractures. The number of prevalent vertebral and non-vertebral fractures varied from 0 to 9 and 0 to 7 in women and 0 to 8 and 0 to 6 in men, respectively. Of the patients who sustained a vertebral fracture, 57 (40.1%), 34 (23.9%), 23 (16.2%) and 28 (19.7%) women, and 11 (61.1%), 3 (16.7%), 2 (11.1%), and 2 (11.1%) men had 1, 2, 3, or 4+ vertebral fractures. A total of 112 (60.5%), 48 (25.9%), 16 (8.6%), and 9 (4.9%) women and 10 (47.6%), 7(33.3%), 1 (4.8%), and 3 (14.3%) men had had 1, 2, 3, or 4+ non-vertebral fractures, respectively. The mean (SD) iliocostal distance for women with a vertebral, non-vertebral and no fracture was 3.49 (1.81) cm, 3.84 (1.69) cm and 4.53 (1.52) cm as compared with 4.22 (1.52) cm, 4.67 (1.43) cm, and 4.77 (1.54) cm for men. Iliocostal distance decreased as the number of vertebral fractures increase in both women and men (table [2](#T2){ref-type="table"}). Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"} present univariate regression analysis results in women and men modelled for the number of vertebral and non-vertebral fractures.

###### 

Baseline characteristics of women and men\*

                                      Women n = 508   Men n = 41
  ----------------------------------- --------------- ---------------
  Age-years (SD)                      61.5 (11.3)     57.8 (12.4)
  Height-cm (SD)                      160.8 (9.6)     174.8 (18.3)
  Weight-kg (SD)                      67.8 (14.4)     86.2 (22.0)
  Iliocostal distance-cm (SD)         4.2 (1.6)       4.6 (1.5)
  Menopausal status-\#post/\#pre      424/78          NA
  Age at menopause-years (SD)         47.3 (6.8)      NA
  Lumbar spine BMD-g/cm^2^ (SD)       0.867 (0.165)   0.918 (0.165)
  Femoral neck BMD-g/cm^2^ (SD)       0.664 (0.112)   0.713 (0.124)
  Trochanter BMD-g/cm^2^ (SD)         0.608 (0.107)   0.676 (0.123)
  Ward\'s triangle BMD-g/cm^2^ (SD)   0.483 (0.133)   0.471 (0.155)
  Currently smoking-\#                64              6
  Family history of fracture-\#       122             12
  Alcohol-beverages/week (SD)         1.4 (3.0)       5.5 (8.7)
  Number of falls -- min to max       0--12           0--4
  Calcium intake-mg/d (SD)            539.0 (435.9)   553.5 (375.4)
  Exercise-minutes/week (SD)          166.7 (165.9)   187.9 (293.0)
  Etidronate use-\# (%)               50 (9.8)        3 (7.3)
  Alendronate use-\# (%)              41 (8.1)        7 (17.1)
  Fluoride use-\# (%)                 2 (0.4)         0 (0.0)
  Raloxifene use-\# (%)               9 (1.8)         0 (0.0)
  Hormone replacement use-\# (%)      146 (28.7)      0 (0.0)
  Corticosteroids use-\# (%)          77 (15.2)       8 (19.5)
  Calcium supplement use-\# (%)       366 (72.0)      16 (39.0)
  Vitamin D supplement use-\# (%)     173 (34.1)      10 (24.4)
  Lung disease^a^-\# (%)              59 (11.6)       3 (7.3)
  Liver disease^b^-\# (%)             13 (2.6)        2 (4.9)
  Thyroid disease^c^-\# (%)           69 (13.6)       0 (0.0)
  Cancer^d^-\# (%)                    14 (2.8)        0 (0.0)
  Visual impairment-\# (%)            51 (10.0)       2 (4.9)
  Osteoporosis-\# (%)                 187 (36.8)      13 (31.7)
  Inflammatory bowel disease-\# (%)   15 (3.0)        5 (12.2)
  Epilepsy-\# (%)                     7 (1.4)         2 (4.9)
  Coronary disease-\# (%)             12 (2.4)        1 (2.4)
  Cerebrovascular disease-\# (%)      19 (3.7)        1 (2.4)
  Rheumatoid arthritis-\# (%)         5 (1.0)         0 (0.0)
  Diabetes-\# (%)                     18 (3.5)        0 (0.0)
  Kidney failure-\# (%)               24 (4.7)        0 (0.0)

\* BMD= bone mineral density; SD= standard deviation; \# = number of patients; %=percent of patients; NA= not applicable. ^a^ Lung disease includes asthma, chronic bronchitis and other lung diseases. ^b^ Liver disease includes cirrhosis, hepatitis and cholangitis. ^c^ Thyroid disease includes hyper, hypo, nodule, and other. ^d^ Cancer includes breast, ovaries, cervix, uterus and colon.

###### 

Iliocostal distance and the number of vertebral and non-vertebral fractures in women and men

                       Women         Men
  -------------------- ------------- -------------
  Vertebral Factures                 
  0\*                  4.53 (1.52)   4.77 (1.54)
  1                    3.90 (1.73)   4.54 (1.57)
  2                    3.79 (1.75)   4.00 (2.00)
  3                    2.91 (1.41)   4.00 (0.00)
  4+                   3.75 (2.06)   3.00 (1.41)

\* Indicates patients without vertebral or non-vertebral fractures.

###### 

Univariate parameter coefficient estimates and P-values for the association between risk factors and the number of vertebral and non-vertebral fractures in women

                                      No. Vertebral fractures   No. Non-Vertebral Fractures            
  ----------------------------------- ------------------------- ----------------------------- -------- ---------
  Age                                 0.034                     \<0.001                       0.018    \<0.001
  Height                              -0.012                    0.083                         0.004    0.454
  Weight                              -0.001                    0.768                         0.002    0.534
  Iliocostal distance                 -0.271                    \<0.001                       -0.115   \<0.001
  Menopausal status                   0.516                     0.003                         0.305    0.015
  Age at menopause                    0.001                     0.917                         -0.006   0.405
  Lumbar spine BMD                    -0.813                    0.048                         -0.722   0.026
  Femoral neck BMD                    -3.069                    \<0.001                       -1.901   \<0.001
  Trochanter BMD                      -3.381                    \<0.001                       -2.415   \<0.001
  Ward\'s triangle BMD                -2.928                    \<0.001                       -1.951   \<0.001
  Prevalent vertebral fractures       NA                                                      0.310    0.002
  Prevalent non-vertebral fractures   0.391                     0.003                         NA       
  Currently smoking                   0.018                     0.759                         0.049    0.258
  Family history of fracture          -0.158                    0.305                         0.121    0.272
  Alcohol-beverages/week              -0.013                    0.529                         -0.012   0.435
  No. of falls                        -0.004                    0.935                         0.079    0.017
  Calcium intake                      -0.000                    0.499                         0.000    0.536
  Exercise                            -0.000                    0.248                         -0.000   0.895
  Etidronate use                      0.315                     0.003                         0.188    0.014
  Alendronate use                     0.250                     0.009                         0.062    0.366
  Fluoride use                        0.392                     0.541                         0.843    0.067
  Raloxifene use                      -0.053                    0.807                         0.167    0.280
  Hormone replacement use             -0.069                    0.551                         -0.001   0.992
  Corticosteroids use                 0.113                     0.308                         -0.046   0.564
  Calcium supplement use              0.302                     0.006                         0.107    0.171
  Vitamin D supplement use            0.147                     0.115                         0.094    0.163
  Lung disease^a^                     0.223                     0.264                         0.334    0.020
  Liver disease^b^                    -0.068                    0.866                         -0.143   0.621
  Thyroid disease^c^                  -0.185                    0.318                         0.060    0.656
  Cancer^d^                           0.327                     0.400                         0.190    0.495
  Visual impairment                   0.136                     0.526                         0.174    0.258
  Osteoporosis                        -0.109                    0.409                         0.002    0.982
  Inflammatory bowel disease          -0.634                    0.091                         0.618    0.022
  Epilepsy                            1.047                     0.054                         -0.175   0.656
  Coronary disease                    0.582                     0.164                         0.401    0.174
  Cerebrovascular disease             1.042                     0.002                         1.016    \<0.001
  Rheumatoid arthritis                0.083                     0.898                         0.403    0.383
  Diabetes                            0.157                     0.648                         0.241    0.328
  Kidney failure                      0.115                     0.700                         0.200    0.352

\* BMD= bone mineral density, NA= not available. ^a^ Lung disease includes asthma, chronic bronchitis and other lung diseases. ^b^ Liver disease includes cirrhosis, hepatitis and cholangitis. ^c^ Thyroid disease includes hyper, hypo, nodule, and other. ^d^ Cancer includes breast, ovaries, cervix, uterus and colon.

###### 

Univariate parameter coefficient estimates and P-values for the association between risk factors and the number of vertebral and non-vertebral fractures in men\*

                                      No. Vertebral fractures   No. Non-Vertebral Fractures            
  ----------------------------------- ------------------------- ----------------------------- -------- -------
  Age                                 0.035                     0.072                         -0.005   0.788
  Height                              -0.034                    0.010                         -0.017   0.164
  Weight                              0.007                     0.523                         0.015    0.155
  Iliocostal distance                 -0.259                    0.095                         -0.037   0.796
  Lumbar spine BMD                    -2.360                    0.174                         -0.399   0.779
  Femoral neck BMD                    -1.378                    0.511                         -0.106   0.953
  Trochanter BMD                      -1.728                    0.410                         -0.822   0.646
  Ward\'s triangle BMD                -2.138                    0.196                         0.275    0.846
  Prevalent vertebral fractures       NA                                                      0.396    0.361
  Prevalent non-vertebral fractures   -0.090                    0.851                         NA       
  Currently smoking                   0.036                     0.876                         0.161    0.443
  Family history of fracture          -0.538                    0.330                         -0.647   0.184
  Alcohol-beverages/week              -0.002                    0.933                         0.043    0.079
  No. of falls                        0.691                     0.002                         0.561    0.006
  Calcium intake-mg/d                 0.001                     0.028                         0.000    0.600
  Exercise-min/week                   -0.000                    0.683                         -0.001   0.484
  Etidronate use                      0.259                     0.574                         -0.180   0.665
  Alendronate use                     0.589                     0.038                         0.036    0.891
  Fluoride use                        NA                                                      NA       
  Raloxifene use                      NA                                                      NA       
  Hormone replacement use             NA                                                      NA       
  Corticosteroids use                 -0.479                    0.286                         0.000    1.000
  Calcium supplement use              -0.014                    0.972                         -0.370   0.279
  Vitamin D supplement use            0.010                     0.977                         0.000    1.000
  Lung disease^a^                     -0.921                    0.315                         0.000    1.000
  Liver disease^b^                    1.205                     0.276                         1.051    0.292
  Thyroid disease^c^                  NA                                                      NA       
  Cancer^d^                           NA                                                      NA       
  Visual impairment                   -0.257                    0.810                         1.635    0.082
  Osteoporosis                        1.003                     0.046                         0.113    0.809
  Inflammatory bowel disease          -0.517                    0.480                         0.000    1.000
  Epilepsy                            -0.897                    0.419                         -1.051   0.292
  Coronary disease                    -0.875                    0.574                         0.000    1.000
  Cerebrovascular disease             3.225                     0.033                         3.075    0.024
  Rheumatoid arthritis                NA                                                      NA       
  Diabetes                            NA                                                      NA       
  Kidney failure                      NA                                                      NA       

\* BMD= bone mineral density, NA= not available. ^a^ Lung disease includes asthma, chronic bronchitis and other lung diseases. ^b^ Liver disease includes cirrhosis, hepatitis and cholangitis. ^c^ Thyroid disease includes hyper, hypo, nodule, and other. ^d^ Cancer includes breast, ovaries, cervix, uterus and colon.

Iliocostal Distance
-------------------

### Women

In women, univariate regression analysis revealed a statistically significant negative association between iliocostal distance and the number of vertebral and non-vertebral fractures (Table [3](#T3){ref-type="table"}). After adjustments were made for confounding variables, multivariable regression analysis showed that iliocostal distance was negatively associated with the number of vertebral fractures (-0.18, CI: -0.27, -0.09; adjusted for bone mineral density at the Ward\'s triangle, epilepsy, cerebrovascular disease, inflammatory bowel disease, etidronate use, and calcium supplement use) and for the number of non-vertebral fractures (-0.09, CI: -0.15, -0.03; adjusted for bone mineral density at the trochanter, cerebrovascular disease, inflammatory bowel disease, and etidronate use).

### Men

In men, univariate regression analysis did not demonstrate a significant association between iliocostal distance and the number of vertebral or non-vertebral fractures (Table [4](#T4){ref-type="table"}). The iliocostal distance variable remained non-significant following multivariable adjustments modelled for the number of vertebral fractures (-0.12, 95% CI: -0.41, 0.16; adjusted for age and the number of fall during the past year) and the number of non-vertebral fractures (0.11, 95% CI: -0.18, 0.41; adjusted for number of falls during year, visual problems that are not corrected by eyeglasses or contacts, and height).

Discussion
==========

Osteoporosis is under-diagnosed, under-treated and a large number of individuals are unaware that they have this disease. With the emergence of effective treatments it is essential to detect those patients with a vertebral fracture and those with at higher risk of fracture. At present, there is no universally accepted policy for identifying patients with osteoporosis. Clinical risk assessment is an important step in identifying individuals at high risk for osteoporosis and fractures. To our knowledge, the relationships between iliocostal distance and the number of prevalent vertebral and non-vertebral fractures have not been previously reported.

Our findings indicated that iliocostal distance is negatively associated with the number of vertebral and non-vertebral fractures in women, such that the shorter the distance the greater number of fractures. Iliocostal distance can be used to identify individuals with vertebral fractures and may be an excellent risk factor for future fractures and should be included in a patient risk profile. This measurement is easy to obtain and assess in a clinical setting, can be measured for all patients, and has a high predictive value for prevalent fracture independent of other known risk factors such as bone mineral density. From our clinical experience, healthy adults have an iliocostal distance of approximately 6 cm.

Vertebral fractures are a well-recognized consequence of postmenopausal bone loss and are the most common osteoporotic fractures \[[@B9]\]. It is estimated that less than one third of all vertebral fractures are clinically diagnosed \[[@B10]\]. A common explanation is that fractures are frequently asymptomatic and patients who suffer them are not prompted to seek medical attention. Furthermore, physicians may not be identifying prevalent fractures among their patients. The early identification of a vertebral fracture is essential. It has been shown that women who develop a vertebral fracture are at increased risk for an additional vertebral fracture \[[@B11]\] and that 20% of women will experience a subsequent fracture within the one year following the first vertebral fracture \[[@B12]\]. Moreover, there is growing evidence that all vertebral fractures are associated with adverse health consequences. Nevitt et al. \[[@B13]\] have found that back pain, functional limitation and disability days are associated with fractures. Among this large cohort of women 65 years of age and older, patients who sustained fractures were 2 to 3 fold more likely to experience more back pain and disability when performing back-dependent activities of daily living as compared with the unaffected comparison group. Likewise, fracture patients were at higher risk of experiencing limited activity days and days confined to bed. Kado et al. \[[@B14]\] observed that women who developed new fractures over a duration of 8 years had a 23% increased risk of mortality. This study also found a dose response effect such that mortality increased with the number of fractures. Accordingly, it is important that physicians recognize patients at risk for vertebral fracture or patients that have sustained fractures.

It is not surprising that iliocostal distance measurements in women were also associated with non-vertebral fractures. Vertebral fractures are early indicators of other osteoporotic fractures \[[@B15]-[@B17]\]. For instance, it has been shown that women who have a prevalent vertebral fracture have an increased relative risk (RR) of a subsequent fracture at the wrist (RR = 1.4), hip (RR = 2.3), and all non-spinal sites (RR = 1.8) as compared with unaffected women \[[@B11]\].

Our results showed that iliocostal distance values were associated with fractures in women but not in men. The apparent differences between women and men are difficult to explain; however, others have found gender differences in risk factors for increased bone loss in an elderly population \[[@B18]\]. Nonetheless, due to the low number of men (n = 41) recruited in this study (and the low statistical power) caution should be taken in the interpretation of the results. Further research will need to be conducted in men to confirm or dispute our findings.

Several features of the study are unique, and thus reinforce our conclusions. For example, all participants were \"real world\" patients who were seen for osteoporosis in a tertiary care setting and thus represent a homogeneous group. Other strengths included the large sample size of women, the careful delineation of potential confounding variables studied, and the wealth of data available about the study cohort. Nonetheless, our study is not without limitations. The study was cross-sectional in design and partially depended on information obtained by recall. Although adjustments were made for several variables, it remains possible that other, unknown determinants of fracture confound the observed associations. Due to the lack of data, no distinction was made between lumbar and thoracic fractures. Moreover, only one investigator assessed iliocostal distance using fingerbreadth as the measurement device, as such future validation of this useful clinical tool in terms of inter-rater reliability is recommended. Not all spinal fractures were confirmed by x-ray. X-rays were performed only in patients with back pain. Therefore, subclinical vertebral fractures may have developed. As a consequence, the actual association between iliocostal distance and the number of vertebral fractures may have been underestimated. The relationship between iliocostal distance and vertebral fractures should be tested in those patients with subclinical fractures.

Conclusions
===========

At present, only a small number of patients at high risk for fracture are currently recognized. Indeed, vertebral fractures often do not produce symptoms, so that many individuals with fractures will not seek medical attention for the problem. However, all vertebral fractures, whether symptomatic or radiographically identified, are associated with increased mortality and morbidity. The challenge for primary care physicians is to prevent, diagnose, and treat osteoporosis as early as possible. Thus, identification is the first step in osteoporosis management. The examination of iliocostal distance may be an excellent clinical opportunity to identify osteoporotic individuals for referral for diagnosis, preventive counseling and management. The identification of high-risk patients is important to effectively use the growing number of available osteoporosis therapies. Longitudinal studies will need to be conducted to determine the association between changes in iliocostal distance measurements and fractures.
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